Venoactive Drugs

Sclerotherapy

Volumn , Issue , 2011, Pages 369-377

  Ramelet, Albert Adrien ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882492027     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-07367-7.00020-0     Document Type: Chapter

References (110)

1. Ramelet AA, Perrin M, Kern P Bounameaux H. Phlebology 2008, Elsevier, Paris. 5th ed.
2. Ramelet AA, Kern P, Perrin M Varicose veins and telangiectasias 2004, Elsevier, Paris.
3. Ramelet AA, Boisseau MR, Allegra C, et al. Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution. Clin Hemorheol Microcirc 2005, 33:309.
4. Nicolaides AN, Allegra C, Bergan J, et al. Management of chronic venous disorders of the lower limbs - guidelines according to scientific evidence. International Angiology 2008, 27:1.
5. Gobin JP, Ramelet AA Place actuelle des médicaments veino-actifs dans le traitement des affections veineuses chroniques. Phlébologie 2008, 61:395.
6. Ramelet AA Management of chronic venous disease: the example of Daflon 500 mg. Phlebolymphology 2009, in press.
7. Diem C The role of oedema protective drugs in the treatment of CVI: a review of evidence based and placebo-controlled clinical trials with regard to efficacy and tolerance. Phlebology 1996, 11:23.
8. Kurtz X Chronic venous insufficiency of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Int Angiol 1999, 18:83.
9. Boada JN, Nazco GJ Therapeutic effect of venotonics in chronic venous insufficiency: a meta-analysis. Clin Drug Invest 1999, 18:413.
10. Clement DL Management of venous edema: insights for an international task force. Angiology 2000, 51:13.
11. Frick RW Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside and Daflon. Angiology 2000, 51:197.
12. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev Jan 2006;25(1):CD003230.
13. Martinez MJ, Bonfill X, Moreno RM, et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev 2005;(3):CD003229.
14. Vanscheidt W, Heidrich H, Jünger M, Rabe E Guidelines for testing drugs for chronic venous insufficiency. Vasa 2000, 29:274.
15. Gohel MS, Davies AH Pharmacological agents in the treatment of venous disease: an update of the available evidence. Curr Vasc Pharmacol 2009, 7:303.
16. Sovak M Grape Extract, resveratrol, and its analogs: a review. J Med Food 2001, 4:93.
17. Badger C, Preston N, Seers K, Mortimer P. Benzo-pyrones for reducing and controlling lymphoedema of limbs. Cochrane Database Syst Rev 2004;(2):CD003140.
18. Vanscheidt W, Rabe E, Nazer-Hijazi B, et al. The efficacy and safety of a coumarin-troxerutin combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo controlled randomized study. Vasa 2000, 31:185.
19. Carpentier PH, Mathieu M Evaluation de l'efficacité clinique d'un médicament veinotrope: les enseignements d'un essai thérapeutique avec la diosmine d'hémisynthèse (Diovénor) dans le syndrome de jambes lourdes. J Mal Vasc 1998, 28:106.
20. Biland L, Blatter P, Scheibler P, et al. On the therapy of so-called leg pains. Controlled double-blind study of the therapeutic efficacy of Daflon (in German). Vasa 1982, 11:53.
21. Behar A, Lagrue G, Cohen-Boulakia F, et al. Study of capillary filtration by double labelling I131-albumin and Tc99m red cells. Application to the pharmacodynamic of Daflon 500 mg. Int Angiol 1988, 7(Suppl 2):35.
22. Cospite M, Dominici A Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency: advantages of the new micronized form. Int Angiol 1989, 8(Suppl 4):61.
23. Barbe R, Amiel M Pharmacodynamic properties and therapeutic efficacy of Daflon 500 mg. Phlebology 1992, (Suppl 2):41.
24. Galley P, Thiollet M A double-blind placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility. Int Angiol 1992, 12:69.
25. Blume I, Langenbahn H, Chamvallins M Quantification of oedema using the volumeter technique: therapeutic application of Daflon 500 mg in CVI. Phlebology 1992, 2:37.
26. Gilly R, Pillion G, Frileux C Evaluation of a new venoactive micronized flavonoid fraction (S 5682) in symptomatic disturbances of the venolymphatic circulation or the lower limb. A double-blind placebo-controlled study. Phlebology 1994, 9:67.
27. Amato C Advantage of a micronized flavonoidic fraction (Daflon 500) in comparison with a micronized diosmin. Angiology 1994, 45:531.
28. Cloarec M, Clement R, Griton P A double-blind clinical trial of hydroxyethylrutosides in the treatment of the symptoms and signs of CVI. Phlebology 1996, 11:76.
29. Guilhou JJ, Dereure O, Marzin L, et al. Efficacy of Daflon 500 mg on venous ulcer healing: a double blind randomized placebo controlled trial. Angiology 1997, 48:77.
30. Ibegbuna V, Nicolaides AN, Sowade O, et al. Venous elasticity after treatment with Daflon 500 mg. Angiology 1997, 48:45.
31. Chassignolle JF, Amiel G, Lanfranchi G, Barbe R Activité thérapeutique de Daflon 500 mg dans l'insuffisance veineuse fonctionnelle. JIM 1999, 99(Suppl):32.
32. Shoab SS, Porter JB, Scurr JH, Coleridge-Smith PD Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease. A prospective study. Eur J Vasc Endovasc Surg 1999, 17:313.
33. Shoab SS, Porter JB, Scurr JH, Coleridge-Smith PD Effect of oral micronised purified flavonoid fraction treatment on leucocyte adhesion molecule expression in patients with chronic venous disease: a pilot study. J Vasc Surg 2000, 31:456.
34. Ramelet AA Pharmacologic aspects of a phlebotropic drug in CVI-associated oedema. Angiology 2000, 5:19.
35. Olszewski W Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema. Angiology 2000, 51:25.
36. Ramelet AA Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency. Angiology 2001, 52:549.
37. Danielsson G, Jungbeck C, Peterson K, Norgren L A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with CVI. Eur J Vasc Endovasc Surg 2002, 23:73.
38. Lyseng-Williamson KA, Perry CM Micronised purified flavonoid fraction: a review of its use in CVI, venous ulcers and haemorrhoids. Drugs 2003, 63:71.
39. Nicolaides AN From symptoms to leg oedema: efficacy of Daflon 500 mg. Angiology 2003, 54(Suppl 1):S33.
40. Roztocyl K, Stvrtinová V, Strejcek J Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with CVI. Int Angiol 2003, 22:1.
41. Coleridge-Smith P, Lok C, Ramelet AA Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg 2005, 30:198.
42. Simsek M, Burak F, Taskin O Effects of micronized purified flavonoid fraction (Daflon) on pelvic pain in women with laparoscopically diagnosed pelvic congestion syndrome: a randomized crossover trial. Clin Exp Obstet Gynecol 2007, 34:96.
43. Pokrovsky AV, Saveljev VS, Kirienko AI, et al. Surgical correction of varicose vein disease under micronized diosmin protection (results of the Russian multicenter controlled trial DEFANS). Angiol Sosud Khir 2007, 13:47.
44. Veverkova L, Kalac J, Jedlicka V, Wechsler J Analysis of surgical procedures on the vena saphena magna in the Czech Republic and an effect of Detralex during its stripping, [in Czech]. Rozhl Chir 2005, 84:410.
45. Das L, Subramanyam Reddy G, Pani S Some observations on the effect of daflon (micronized purified flavonoid fraction of rutaceae aurantiae) in bancroftian filarial lymphoedema. Filaria J 2003, 2:5.
46. Wright DD, Franks PJ, Blair SD, et al. Oxerutins in the prevention of recurrence in chronic venous ulceration: a randomized controlled trial. Br J Surg 1991, 78:1269.
47. Kranendonk SE, Koster AM A double-blind clinical trial of the efficacy and tolerability of O-(?-hydroxyethyl)-rutosides and compression stockings in the treatment of leg oedema and symptoms following surgery for varicose veins. Phlebology 1993, 8:77.
48. Rehn D, Golden G, Nocker W, et al. Comparison between the efficacy and tolerability of oxerutins and troxerutin in the treatment of patients with CVI. Arzneimittelforschung 1993, 10:1060.
49. Vin F, Chabanel A, Taccoen A, et al. Double blind trial of the efficacy of troxerutin on chronic venous insufficiency. Phlebology 1994, 9:71.
50. Diebschlag W, Nocker W, Lehmacher D, Rehn D A clinical comparison of two doses of O-(?-hydroxyethyl)-rutosides (oxerutins) in patients with CVI. J Pharm Med 1994, 4:7.
51. Poynard T, Valterio C Meta analysis of hydroxyethyl rutosides in the treatment of chronic venous insufficiency. Vasa 1994, 23:244.
52. Unkauf M, Rehn D, Klinger J, et al. Investigation of the efficacy of oxerutins compared to placebo in patients with CVI treated with compression stockings. Arzneimittelforschung 1996, 46:478.
53. Incandela L, De Sanctis MT, Cesarone MR, et al. Efficacy of troxerutin in patients with chronic venous insufficiency: a double blind, controlled study. Adv Ther 1996, 13:161.
54. Carlsson K, Patwardhan A, Poullain JC, Gerentes I Transport and localization of troxerutin in the venous wall. J Mal Vasc 1996, 21(Suppl C):270.
55. Grossmann K Vergleich der Wirksamkeit einer kombinierten Therapie mit Kompressionstrümpfen und Oxerutin (Venoruton) versus Kompressionsstrümpfe und Placebo bei Patienten mit CVI. Phlebologie 1997, 26:105.
56. Incandela L, Belcaro G, Renton S, et al. HR (Paroven; O-(?-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo controlled, randomized trial. J Cardiovasc Pharmacol Ther 2002, 7(Suppl 1):S7.
57. Petruzellis V, Troccoli T, Candiani C, et al. Oxerutins (Venoruton): efficacy in CVI: a double blind, randomized, controlled study. Angiology 2002, 53:257.
58. Marshall M, Loew D, Schwahn-Schreiber C Hydroxyethylrutoside zur Behandlung der chronischen Veneninsuffizienz Grad I und II. Phlebologie 2005, 34:157.
59. Diehm C, Vollbrecht D, Amendt K, Comberg HU Medical edema protection - clinical benefit in patients with chronic deep vein incompetence. A placebo controlled double blind study. Vasa 1992, 21:188.
60. Diehm C, Trampisch HJ, Lange S, Schmidt C Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet 1996, 347:292.
61. Pittler MH, Ernst E Horse chestnut seed extract for chronic venous insufficiency: a criteria-based systematic review. Arch Dermatol 1998, 134:1356.
62. Koch R Comparative study of Venostasin and Pycnogenol in CVI. Phytotherapy Res 2002, 16:S1.
63. Siebert U, Brach M, Scrozynski G, Berla K Efficacy, routine effectiveness and safety of horse chestnut seed extract in the treatment of CVI: a meta analysis of randomized controlled trials and large observational studies. Int Angiol 2002, 21:305.
64. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev 2004;(2):CD003230.
65. Cappelli R, Nicora M, Di Perri T Use of extract of Ruscus aculaeatus in venous diseases of the lower limbs. Drugs Exp Clin Res 1988, 4:277.
66. Le Devehat C, Khodabandehlou T, Vimeux M, Dougny M The effect of Cyclo 3 Fort® treatment on hemorheological disturbances during a provoked venous stasis in patients with chronic venous insufficiency. Clin Hemorheol Micorocirc 1994, 14:S53.
67. Parrado F, Buzzi A A study of the efficacy and tolerability of a preparation containing Ruscus aculeatus in the treatment of CVI of the lower limbs. Clin Drug Invest 1999, 18:255.
68. Jäger KA, Eichlisberger R, Jeanneret CH, Labs KH Pharmacodynamic effects of Ruscus extract (Cyclo 3 Fort) on superficial and deep veins in patients with primary varicose veins: assessment by duplex sonography. Clin Drug Invest 1999, 17:265.
69. Beltranimo R, Penenory A, Buceta AM An open label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 fort versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency. Angiology 2000, 51:535.
70. Bouaziz N, Michiels C, Janssens D, et al. Effect of Ruscus extract and hesperidin methylchalcone on hypoxia-induced activation of endothelial cells. Int Angiol 1999, 18:306.
71. Vanscheidt W, Jost V, Wolna P, et al. Efficacy and safety of a Butcher's broom preparation compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittelforschung 2002, 52:243.
72. Boyle P Meta-analysis of clinical trials of Cyclo 3 Fort in the treatment of chronic venous insufficiency. Int Angiol 2003, 22:250.
73. Lascasas Porto CL, Milhomens AL, Pires CE, et al. Changes on venous diameter and leg perimeter with different clinical treatments for moderate chronic venous disease: evaluation using Duplex scanning and perimeter measurements. Int Angiol 2009, 28:222.
74. Guex JJ, Enriquez Vega DM, Avril L, et al. Assessment of quality of life in Mexican patients suffering from chronic venous disorder - impact of oral Ruscus aculeatus-hesperidin-methyl-chalcone-ascorbic acid treatment - 'QUALITY Study'. Phlebology 2009, 24:157.
75. Natali J Gingkor Fort et maladie veineuse. Angiologie 1989, 102:3.
76. Arnould T, Michiels M, Janssens D, et al. Effect of Ginkor Fort on hypoxia induced neutrophil adherence to human saphenous vein endothelium. Int J Clin Pharmacol Res 1994, 14:95.
77. Zucarelli F Evaluation de l'efficacité de Ginkor Fort sur la symptomatologie fonctionnelle de l'insuffisance veineuse chronique. Angiologie 1996, 49:1.
78. Janssens D, Michiels C, Guillaume G, et al. Increase of circulating endothelial cells in patients with primary chronic venous insufficiency: protective effect of Ginkor Fort in a randomized double-blind, placebo-controlled clinical trial. J Cardiovasc Pharmacol 1999, 33:7.
79. Allegra C, Pollari G, Criscuolo A, et al. L'estratto di centella asiatica nelle flebopatie degli arti inferiori. Ricorca clinco-stratamentale conparativa con un placebo. Clin Ter 1988, 199:507.
80. Cataldi A, Gasbarro V, Viaggi R, et al. Effectiveness of the combination of alpha tocopherol, rutin, melitolotus and centella asiatica in the treatment of chronic venous insufficiency [in Italian]. Minerva Cardioangiol 2001, 49:159.
81. Kiesewetter A, Koscielny J, Kalus U, et al. Efficacy of orally administered extract of red wine leaf AS 195 in chronic venous insufficiency (stages I-II). A randomized double blind, placebo controlled trial. Arzneimittelforschung 2000, 50:109.
82. Constantini A, Bernardi T, Gotti A Clinical and capillaroscopic evaluation of chronic uncomplicated venous insufficiency with procyanidins extracted from vitis vinifera [in Italian]. Minerva Cardioangiol 1999, 47:39.
83. Petrassi C, Mastromarino A, Spartera C Pycnogenol in CVI. Phytomedicine 2000, 7:383.
84. Rohdewald P A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther 2002, 40:158.
85. Arcangeli P Pycnogenol in chronic venous insufficiency. Fitoterapia 2000, 71:236.
86. Casley-Smith JR A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology 1988, 10:853.
87. Widmer L, Biland L, Barras JP Doxium 500 in chronic venous insufficiency: a double blind placebo controlled multicenter study. Int Angiol 1990, 9:105.
88. Angehrn F Efficacy and safety of calcium dobesilate in patients with chronic venous insufficiency: an open label multicenter study. Curr Ther Res 1995, 56:346. on behalf of the Swiss study group.
89. Arceo A, Berber A, Trevino C Clinical evaluation of the efficacy and safety of calcium dobesilate in patients with chronic venous insufficiency of the lower limbs. Angiology 2002, 53:539.
90. Allain H, Ramelet AA, Polard E, Bentue-Ferrer D Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf 2004, 27:649.
91. Iriz E, Vural C, Ereren E, et al. Effects of calcium dobesilate and diosmin-hesperidin on apoptosis of venous wall in primary varicose veins. Vasa 2008, 37:233.
92. Flota-Cervera F, Flota-Ruiz C, Treviño C, Berber A Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology 2008, 59:352.
93. Ciapponi A, Laffaire E, Roque M Calcium dobesilate for chronic venous insufficiency: a systemic review. Angiology 2004, 55:147.
94. Labs KH, Degisher S, Gamba G, Jaeger KA Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized double blind placebo controlled trial. Phlebology 2004, 19:123. on behalf of the CVI study group.
95. Rabe E, Jaeger K Multicentre, double blind, placebo-controlled, randomised clinical study to assess the efficacy and safety of Doxium 500 three times daily in patients suffering from CVI CEAP class C3,4 or 5. Phlebologie 2006, 35:A37.
96. Martínez-Zapata MJ, Moreno RM, Gich I, et al. Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. Eur J Vasc Endovasc Surg 2008, 35:358.
97. Hautekeete ML Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities. Liver 1995, 15:25.
98. Vayssairat M Placebo-controlled trial of naftazone in women with primary uncomplicated symptomatic varicose veins. Phlebology 1997, 12:17. and the French Venous Naftazone Trial Group.
99. Zicot M Etude multicentrique de l'efficacité et de la tolérance de la Naftazone (Mediaven 10 mg). Comparaison de deux schémas posologiques. Rev Med Liège 1993, 158:224.
100. Forconi S, Guerrini M, Pecchi S, et al. Effect of HR(O-(beta-hydroxyl)-rutosides) on the impaired venous function of young females taking oral contraceptives: a strain gauge plethysmographic and clinical open controlled study. Vasa 1980, 9:324.
101. Allaert FA, Vin F, Levardon M Comparative study of the effectiveness of continuous or intermittent courses of a phlebotonic drug on venous disorders disclosed or aggravated by oral oestrogen-progesterone contraceptives. Phlebologie 1992, 45:167.
102. Serfaty D, Magneron AC Premenstrual syndrome in France: epidemiology and therapeutic effectiveness of 1000mg of micronized purified flavonoid fraction in 1473 gynecological patients [in French]. Contracept Fertil Sex 1997, 25:85. 1997.
103. Lefebvre G, Lacombe C Venous insufficiency in the pregnant woman. Rheological correction by troxerutin. Rev Fr Gynecol Obstet 1991, 86:206.
104. Marhic C Clinical and rheological efficacy of troxerutin in obstetric gynaecology. Rev Fr Gynecol Obstet 1991, 86:209.
105. Young GL, Jewell D. Interventions for varicosities and leg oedema in pregnancy. Cochrane Database Syst Rev 1998;(1):CD001066.
106. Gouny AM, Horovitz D, Gouny P, et al. Etude d'efficacité et de tolérance des Hydroxyéthyl-rutosides dans le traitement local des symptômes d'insuffisance veineuse survenant au cours des transports aériens. J Mal Vasc 1999, 24:214.
107. Wetzel D, Menke W, Dieter R, et al. Escin/diethylammonium salicylate/heparin combination gels for the topical treatment of acute impact injuries: a randomised, double blind, placebo controlled, multicentre study. Br J Sports Med 2002, 36:183.
108. Gloviczki PDM, Eklöf B, Moneta GL, Wakefield TW Handbook of venous disorders: guidelines of the American Venous Forum 2009, Hodder Arnold, London, p. 359. 3rd ed.
109. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edn. Chest 2008, 133(Suppl 6):454S-545S.
110. Allegra C Chronic venous insufficiency: the effects of health-care reforms on the cost of treatment and hospitalisation - an Italian perspective. Curr Med Res Opin 2003, 19:761.